SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.52+0.4%Nov 28 12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (8939)8/14/2003 5:53:01 PM
From: Biomaven  Read Replies (2) of 52153
 
Erik,

I sold my NPSP in early June at a little over $29 (but still have my NBIX). But maybe NPSP deserves another look at this lower price.

I guess Preos will be the principle mid-term value driver. Forteo sales have not been spectacular ($14m in the latest quarter after a 12/02 launch), so that casts some doubt on Preos's value. Have you seen any sort of comparison between the two drugs?

Can anyone remind me what the Cinacalcet royalty terms are like?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News